Coronaviruses follow a tightly coordinated sequence of events to hijack a host cell, copy their genome, assemble new virus particles, and escape to infect neighboring cells. Each stage depends on specialized viral proteins that interact with host machinery in surprisingly precise ways. The spike protein, the replication complex, the main protease, and a handful of accessory proteins each play roles that researchers have now mapped in structural and biochemical detail, revealing both elegant biology and promising targets for antiviral drugs.
How the Virus Gets Inside a Cell
Entry begins with the spike glycoprotein, the large, crown-like projection that gives coronaviruses their name. The spike is a class I fusion protein responsible for two jobs: binding a receptor on the host cell surface and then fusing the viral and host membranes together so the genome can slip through.1PubMed Central. Mechanisms of coronavirus cell entry mediated by the viral spike protein Different coronaviruses use different receptors. SARS-CoV and SARS-CoV-2 latch onto ACE2, MERS-CoV targets DPP4, several alphacoronaviruses bind aminopeptidase N, and mouse hepatitis virus uses a cell-adhesion molecule called CEACAM1.2FEMS Microbiology Reviews. Molecular diversity of coronavirus host cell entry receptors This diversity is partly why different coronaviruses infect different species and different tissues.
The receptor-binding regions of various coronavirus spikes are themselves diverse and can be located on different parts of the protein, yet distantly related coronaviruses sometimes converge on the same receptor while closely related ones diverge onto separate receptors.3PubMed Central. Receptor recognition mechanisms of coronaviruses: a decade of structural studies That complexity helps explain why predicting which animal coronaviruses could jump to humans is so difficult.
Binding the receptor is only half the problem. For SARS-CoV-2, the spike must be cut at two sites by host enzymes before it can trigger membrane fusion. The first cut, at the boundary between the S1 and S2 subunits, is made by a protease called furin and causes a shape change in the spike that actually improves its ability to grab ACE2. The second cut, at a site called S2′, is what unleashes the fusion machinery.4PubMed Central. Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity Blocking furin with inhibitors can suppress virus production and the cell damage that comes with it.5PubMed Central. Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects
Where fusion actually happens depends on what the cell has available. If there is enough of a surface protease called TMPRSS2, the spike gets cleaved right at the plasma membrane and the virus fuses in. If the cell has little TMPRSS2, the virus-receptor complex gets pulled inside through a process called endocytosis and ends up in an acidic compartment, where a different set of enzymes called cathepsins make the critical S2′ cut instead.6Nature Reviews Molecular Cell Biology. Mechanisms of SARS-CoV-2 entry into cells This flexibility in entry pathways is one reason SARS-CoV-2 infects such a wide range of cell types.
Translating the Viral Genome Into Working Proteins
Once the genome, a single strand of positive-sense RNA roughly 30,000 nucleotides long, reaches the host cell’s cytoplasm, the cell’s own ribosomes begin reading it immediately, as if it were a normal messenger RNA. The first two-thirds of the genome encodes two enormous polyproteins. Most of the time, ribosomes make the shorter version, pp1a. But a cleverly folded RNA structure near the end of the pp1a reading frame causes ribosomes to slip backward by one nucleotide on a fraction of their passes, a trick called programmed ribosomal frameshifting. When they slip, they continue reading into a second open reading frame and produce a much longer polyprotein, pp1ab.7PubMed Central. The role of programmed-1 ribosomal frameshifting in coronavirus propagation The longer polyprotein includes the virus’s RNA-copying enzyme, the RNA-dependent RNA polymerase, which is essential for everything that follows.
The RNA structure that triggers frameshifting, known as a pseudoknot, folds into a three-stemmed shape that stalls the ribosome at just the right spot.8PubMed Central. The SARS-CoV-2 Programmed −1 Ribosomal Frameshifting Element Crystal Structure Solved to 2.09 Å Using Chaperone-Assisted RNA Crystallography Drugs or mutations that destabilize this pseudoknot throw off the balance between pp1a and pp1ab proteins, crippling replication. Across different coronaviruses, the relationship between pseudoknot structure and frameshifting efficiency turns out to be surprisingly varied; the structural rules that govern frameshifting in SARS-CoV-2 do not fully apply to other coronavirus species.9PubMed Central. RNA Structural Ensemble Determinants of -1 Programmed Ribosomal Frameshifting Efficiency Across Coronavirus Evolution
The polyproteins themselves are not functional until they are chopped into individual pieces. Two viral proteases do this work. The main protease, known as Mpro, handles most of the cuts: it frees itself from the polyprotein, pairs up with a partner copy of itself, and then sequentially cleaves 11 of the 15 junctions between the nonstructural proteins encoded in pp1ab.10PubMed Central. Kinetic comparison of all eleven viral polyprotein cleavage site processing events by SARS-CoV-2 main protease using a linked protein FRET platform A second protease, called papain-like protease, handles the remaining four. Together they liberate all the nonstructural proteins needed for genome copying, RNA capping, and immune evasion.11PubMed Central. Structural basis for replicase polyprotein cleavage and substrate specificity of main protease from SARS-CoV-2
Replication Inside Membrane Shelters
Coronaviruses do not copy their genome out in the open cytoplasm. Instead, they reshape the cell’s internal membranes, particularly the endoplasmic reticulum, into clusters of double-membrane vesicles that act as protective workshops. Two viral nonstructural proteins, nsp3 and nsp4, are sufficient to drive this membrane remodeling, and host proteins called reticulons physically interact with them to help form the vesicles.12PubMed Central. Expression and Cleavage of Middle East Respiratory Syndrome Coronavirus nsp3-4 Polyprotein Induce the Formation of Double-Membrane Vesicles That Mimic Those Associated with Coronaviral RNA Replication13Journal of Cell Biology. Reticulons promote formation of ER-derived double-membrane vesicles that facilitate SARS-CoV-2 replication Inside these vesicles, double-stranded RNA intermediates are tucked away from the cell’s innate immune sensors, which would otherwise sound the alarm.
The core copying enzyme, nsp12 (the RNA-dependent RNA polymerase), works with several helper proteins. Nsp7 and nsp8 act as cofactors that grip the RNA template, while nsp13, a helicase, unwinds secondary structures in the template and can switch the polymerase between forward synthesis and a backward-tracking mode that may help resolve errors.14PubMed Central. Ensemble cryo-EM reveals conformational states of the nsp13 helicase in the SARS-CoV-2 helicase replication-transcription complex The polymerase copies the full-length genome for packaging into new virions, but it also makes a set of shorter messenger RNAs (called subgenomic mRNAs) that encode the structural proteins like spike, envelope, membrane, and nucleocapsid.
Making those subgenomic messages involves one of the most unusual features in all of RNA virology: discontinuous transcription. The polymerase starts copying from the end of the genome, but when it hits a specific signal sequence upstream of each gene, it can jump to the very beginning of the genome and paste on a short leader sequence.15PubMed Central. Continuous and Discontinuous RNA Synthesis in Coronaviruses The result is a nested set of messages, each containing the same leader at the front. How well the signal sequences match their counterpart near the leader helps determine how much of each subgenomic RNA is made, giving the virus a way to regulate the amounts of its different proteins.16PubMed Central. Role of nucleotides immediately flanking the transcription-regulating sequence core in coronavirus subgenomic mRNA synthesis
A Built-In Proofreader
At roughly 30,000 nucleotides, coronavirus genomes are the largest among RNA viruses. Most RNA viruses have error-prone polymerases and rely on rapid mutation for adaptability, which limits how big their genomes can get before too many harmful mutations accumulate. Coronaviruses solved this problem by evolving a proofreading enzyme: a 3′-to-5′ exoribonuclease within nonstructural protein 14 (nsp14).17PubMed Central. Proofreading-Deficient Coronaviruses Adapt for Increased Fitness over Long-Term Passage without Reversion of Exoribonuclease-Inactivating Mutations This enzyme trims off mismatched nucleotides that the polymerase accidentally adds, including some antiviral drug molecules that mimic normal building blocks.18PubMed Central. Structure and dynamics of SARS-CoV-2 proofreading exoribonuclease ExoN
The existence of this proofreader has practical consequences for drug design. Remdesivir, for example, works partly by getting incorporated into the growing RNA chain and stalling the polymerase. But nsp14 can excise it in some contexts, which is why researchers have explored combination strategies and drugs like molnupiravir that evade proofreading through a different mechanism.
Assembly and Packaging
New virus particles come together at a membrane compartment called the ERGIC, a structure positioned between the endoplasmic reticulum and the Golgi apparatus.19PubMed Central. Coronavirus envelope (E) protein remains at the site of assembly The structural proteins, spike (S), membrane (M), and envelope (E), are inserted into ERGIC membranes after being translated from their subgenomic mRNAs. Meanwhile, the nucleocapsid (N) protein gathers up the freshly copied full-length genome in the cytoplasm.
The N protein’s packaging role involves a process called phase separation, where N protein and genomic RNA condense into liquid-like droplets. Research on SARS-CoV-2 shows that different regions of the genome influence this condensation in different ways: the 5′ and 3′ ends promote droplet formation while central regions have a solubilizing effect. This patterning may help the virus distinguish its full-length genome from the shorter subgenomic messages and from the cell’s own RNA, ensuring that the right molecule gets packaged.20Journal of Biological Chemistry. Phase separation by the SARS-CoV-2 nucleocapsid protein: Consensus and open questions The N protein shows classic re-entrant phase behavior with RNA, meaning that the right ratio of protein to RNA is critical: too much or too little of either and the droplets dissolve.21Nature Communications. The SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA
The genome-loaded nucleocapsid then buds into the ERGIC membrane, acquiring its lipid envelope and the embedded structural proteins. The M protein orchestrates much of this budding, interacting with both the N protein and the cytoplasmic tails of S and E. The result is a fully formed virion sitting inside a membrane-bound vesicle, ready to be transported out of the cell.
Escaping the Cell
For years, the assumption was that coronaviruses simply exited cells through the same secretory pathway that delivers cargo to the cell surface. That picture changed when researchers discovered that SARS-CoV-2 and related betacoronaviruses hijack the lysosomal exocytosis pathway instead. Lysosomes, normally the cell’s recycling centers, get redirected to the plasma membrane where they dump their contents, including virus particles, outside the cell.22PubMed Central. ORF3a of SARS-CoV-2 promotes lysosomal exocytosis-mediated viral egress
A small viral protein called ORF3a drives this rerouting. SARS-CoV-2’s version of ORF3a promotes the trafficking of lysosomes toward the cell surface and recruits the molecular machinery needed for membrane fusion at the plasma membrane. A calcium channel called TRPML3 is required for this process. Strikingly, the original SARS-CoV’s version of ORF3a cannot do this, which may partly explain differences in how efficiently these two viruses spread.23Developmental Cell. ORF3a of the COVID-19 virus SARS-CoV-2 promotes lysosomal exocytosis
How the Virus Hides From the Immune System
Coronaviruses deploy several strategies to delay or suppress the host’s innate immune response during replication. One of the earliest-acting is Nsp1, the first protein released from the polyprotein. Nsp1 binds to the host ribosome and physically blocks it from translating host messenger RNAs, while simultaneously triggering the destruction of those messages. Viral mRNAs escape this fate through structural features in their leader sequence, meaning the virus effectively shuts down host protein production while keeping its own humming along.24PubMed Central. The art of hijacking: how Nsp1 impacts host gene expression during coronaviral infections25PubMed Central. An Evolutionarily Conserved Strategy for Ribosome Binding and Host Translation Inhibition by β-coronavirus Non-structural Protein 1 This strategy is conserved across betacoronaviruses, suggesting it confers a strong selective advantage.
A second evasion strategy involves disguising viral RNA to look like the cell’s own. Host cells can detect foreign RNA partly because it lacks certain chemical modifications. Coronaviruses counter this by capping their RNA at the 5′ end and adding methyl groups. The nsp10/nsp16 complex performs the final step, adding a methyl group to the ribose sugar of the first nucleotide after the cap. This 2′-O methylation prevents the RNA from being recognized by host sensors that would otherwise trigger interferon production.26PubMed Central. 2′-O methylation of RNA cap in SARS-CoV-2 captured by serial crystallography The enzyme complex specifically requires that the cap already has a methyl group on its N7 position before it will act, a sequential quality-control step that ensures complete capping.27PLoS Pathogens. Crystal Structure and Functional Analysis of the SARS-Coronavirus RNA Cap 2′-O-Methyltransferase nsp10/nsp16 Complex
Yet another trick involves manipulating autophagy, the cell’s internal cleanup system. The SARS-CoV-2 ORF7a protein activates the early steps of autophagy, causing the cell to form autophagosomes, but then blocks the final step where those autophagosomes would fuse with lysosomes and destroy their contents. The accumulated autophagosomes actually help the virus replicate. ORF7a achieves this sabotage by activating a host enzyme that cuts a protein called SNAP29, which is needed for the final fusion step.28PubMed Central. The ORF7a protein of SARS-CoV-2 initiates autophagy and limits autophagosome-lysosome fusion via degradation of SNAP29 to promote virus replication
Syncytia and Cell-to-Cell Spread
Coronaviruses do not rely solely on releasing free-floating particles to infect new cells. Spike protein displayed on the surface of an infected cell can grab ACE2 on a neighboring cell and fuse the two cells together, creating a giant multinucleated cell called a syncytium.29PubMed Central. Syncytia formation by SARS‐CoV‐2‐infected cells This can happen with spike alone, without any other viral protein present. In laboratory experiments with endothelial cells, about 11% of cells had fused into syncytia by 72 hours, with each syncytium averaging around 6 nuclei, and larger ones sometimes tore away from the surrounding tissue and left gaps behind.30Scientific Reports. SARS-CoV-2 S-protein expression drives syncytia formation in endothelial cells
Cell-to-cell transmission through this route appears to be more efficient for SARS-CoV-2 than for the original SARS-CoV, partly because the SARS-CoV-2 spike is better at driving cell-cell fusion.31PubMed Central. SARS-CoV-2 spreads through cell-to-cell transmission This mode of spread may help the virus dodge neutralizing antibodies in the extracellular space, since the genome never has to leave the protection of a cell membrane. Syncytia have been found in lung tissue from patients with severe COVID-19 and are thought to contribute to tissue damage.
Recombination and New Strains
The discontinuous transcription mechanism that produces subgenomic mRNAs also predisposes coronaviruses to something dangerous: genetic recombination. When two different coronaviruses infect the same cell simultaneously, their polymerases can switch between templates and stitch together hybrid genomes. Recombination is considered a key driver of coronavirus spillover into new host species.32PubMed Central. The coronavirus recombination pathway
How often does this actually happen? In co-infection experiments with two related animal coronaviruses, recombinant RNA molecules were detected in every replicate, though they made up on average only about 0.05% of all viral reads. Researchers even observed full-length recombinant genomes, each unique, suggesting that functional recombinant viruses could potentially emerge from such events. The rate of recombination tracked closely with how many cells were infected by both viruses at once, which itself was driven by the amount of virus and the time allowed for infection to spread.33PubMed Central. Cellular dynamics shape recombination frequency in coronaviruses In other words, the more co-infection a population of cells experiences, the more recombination occurs. This has implications for monitoring situations where multiple coronavirus strains or species circulate in the same animal host.
How Antiviral Drugs Target Different Stages
The detailed understanding of the coronavirus life cycle has directly informed the design of antiviral drugs, and the three small-molecule antivirals authorized for COVID-19 each target a distinct stage. Nirmatrelvir (the active component of Paxlovid) blocks the main protease, Mpro, preventing the polyproteins from being cut into functional pieces. Remdesivir mimics a natural nucleotide building block and gets incorporated into the growing RNA chain by the polymerase, causing the chain to stall. Molnupiravir also targets the polymerase but works differently: once incorporated, it causes the polymerase to introduce so many random mutations in subsequent rounds of copying that the resulting genomes are nonfunctional, a process sometimes called error catastrophe.34PubMed Central. Viral target and metabolism-based rationale for combined use of recently authorized small molecule COVID-19 medicines: Molnupiravir, nirmatrelvir, and remdesivir
Each drug has a distinct vulnerability to the virus’s own defenses. Remdesivir, as an adenosine analog, can sometimes be excised by the nsp14 proofreader, potentially reducing its effectiveness. Molnupiravir’s mutagenic mechanism largely sidesteps proofreading because the mismatches it introduces are not always recognized as errors during the copying cycle in which they are first made. Nirmatrelvir avoids the proofreading problem entirely because it targets a protease, not the replication complex. This is part of the rationale for exploring combination therapies that hit multiple stages of the life cycle at once.35PubMed Central. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2
Beyond these approved drugs, several other life-cycle stages are being explored as therapeutic targets. The frameshifting pseudoknot, the cap-methylation enzymes, the ORF3a-driven egress pathway, and the nsp3/nsp4-mediated membrane remodeling step are all under active investigation. The frameshifting element is an appealing target because disrupting it throws off the balance of all downstream nonstructural proteins at once. The cap-methylation enzymes are attractive because blocking them would expose viral RNA to the host’s own immune sensors. Whether any of these approaches will yield clinical drugs remains to be seen, but the density of druggable targets across the coronavirus life cycle is unusual among RNA viruses and is a direct consequence of how complex and specialized that life cycle is.